ERBB2 and breast cancer: We further demonstrated that HS-27 can be used to treat aggressive Her2+ and triple negative (TNBC) breast cancers by degrading an Hsp90 client protein involved in cell metabolism, down-regulating both glycolytic and oxidative metabolism leading to decreased cell proliferation.